Lotus Pharmaceuticals, Inc.
LTUS
$0.0053
-$0.0007-11.67%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 19.04M | 18.69M | 12.92M | 20.14M | 18.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.04M | 18.69M | 12.92M | 20.14M | 18.30M |
| Cost of Revenue | 15.73M | 13.81M | 6.76M | 9.64M | 7.93M |
| Gross Profit | 3.31M | 4.89M | 6.15M | 10.50M | 10.38M |
| SG&A Expenses | 1.58M | 2.41M | 3.18M | 8.17M | 3.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.78M | 16.91M | 10.67M | 17.88M | 11.55M |
| Operating Income | 1.27M | 1.79M | 2.25M | 2.26M | 6.76M |
| Income Before Tax | 1.25M | 1.77M | 2.24M | -3.78M | 6.90M |
| Income Tax Expenses | -- | -- | 100.00 | -250.20K | 200.30K |
| Earnings from Continuing Operations | 1.25M | 1.77M | 2.24M | -3.53M | 6.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.25M | 1.77M | 2.24M | -3.53M | 6.70M |
| EBIT | 1.27M | 1.79M | 2.25M | 2.26M | 6.76M |
| EBITDA | 1.68M | 2.20M | 2.66M | 3.17M | 7.21M |
| EPS Basic | 0.05 | 0.06 | 0.08 | -0.13 | 0.25 |
| Normalized Basic EPS | 0.03 | 0.04 | 0.05 | 0.07 | 0.16 |
| EPS Diluted | 0.04 | 0.06 | 0.08 | -0.13 | 0.25 |
| Normalized Diluted EPS | 0.03 | 0.04 | 0.05 | 0.07 | 0.16 |
| Average Basic Shares Outstanding | 27.78M | 27.75M | 27.49M | 26.71M | 26.70M |
| Average Diluted Shares Outstanding | 28.09M | 28.06M | 27.80M | 26.71M | 27.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |